Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 11/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.40 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.40 |
| ▸ | CPN1 | P15169 | 1/20 | 0.39 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15474131 | 0.87 | DPP4 (0.41) | EPHX2ALDH1A1NPC1CPN1CPB2 | |
| SCHEMBL12876398 | 0.84 | EPHX2 (0.50) | EPHX2ALDH1A1CHRNB2CHRNA3CHRNA4 | |
| SCHEMBL14238179 | 0.84 | GAA (0.41) | ALDH1A1NPC1CPN1CPB2 | |
| SCHEMBL11990220 | 0.83 | HPGD (0.48) | ALDH1A1CHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL7883168 | 0.82 | PIK3CD (0.46) | EPHX2EPHX1CPN1CPB2 | |
| SCHEMBL13245899 | 0.82 | EPHX2 (0.49) | EPHX2ALDH1A1CHRNB2CHRNA3CHRNA4 | |
| SCHEMBL14147080 | 0.82 | ALDH1A1 (0.46) | ALDH1A1 | |
| SCHEMBL11990249 | 0.81 | ALDH1A1 (0.40) | ALDH1A1NPC1CPN1CPB2 | |
| SCHEMBL14018532 | 0.81 | EPHX2 (0.47) | EPHX2ALDH1A1CHRNB2CHRNA3CHRNA4 | |
| SCHEMBL15247196 | 0.80 | NPC1 (0.41) | ALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210188843-A1 | QUINOLINE COMPOUNDS AND THEIR PREPARATION AND USE AS ANTIMALARIAL AGENTS | THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2021-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210188843-A1 | QUINOLINE COMPOUNDS AND THEIR PREPARATION AND USE AS ANTIMALARIAL AGENTS | GLS2, RECQL, PYGL | EPHX2 2677/4885ALDH1A1 866/4885CHRNB2 1776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.